WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

Firm News

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins, a novel target space for precision cancer therapies. The Column Group, Atlas Venture and EcoR1 Capital provided the investment.

The WilmerHale team advising Accent was led by Stuart Falber and included Jenna Ventorino and Alex Civetta.

Read Accent Therapeutics' press release for more information.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.